Cumulus Neuroscience Reveals Findings at ISCTM Conference

Cumulus Neuroscience showcased significant interim data at the International Society for CNS Clinical Trials and Methodology (ISCTM) Autumn Conference in Philadelphia, indicating promising results for its NeuLogiq® Platform in remote brain monitoring for borderline personality disorder and therapy-resistant depression.

The company reported findings from three studies, two of which were conducted in partnership with a major pharmaceutical firm and academic collaborators. The research focuses on enhancing clinical trial methodologies for central nervous system disorders by using frequent digital measurements, which could potentially reshape trial designs.

The first study, centered on borderline personality disorder (BPD), involved 51 participants and used a combination of EEG, cognitive assessments, and mood ratings. Interim data showed that participants adhered to NeuLogiq assessments with over 85% compliance, indicating strong engagement with the digital tools. The study's authors noted that this high adherence rate meets the necessary benchmarks for clinical trials that aim to minimize in-person visits.

In a second study addressing therapy-resistant depression, researchers monitored 54 patients undergoing esketamine treatment. Results indicated that 98.7% of in-clinic sessions and 90.5% of at-home assessments were completed successfully. The authors concluded that the approach is feasible and well-received by patients, allowing for effective data collection in a natural clinical setting.

The third poster presented a digital cognitive task, known as Symbol Swap, designed for pre-enrichment screening in Alzheimer's trials. This two-minute task was evaluated across multiple studies, demonstrating its ability to discriminate between different cognitive states effectively, outperforming traditional methods in terms of efficiency and participant burden.

The findings presented at ISCTM suggest that Cumulus Neuroscience's digital tools can enhance patient engagement and data quality in CNS trials, potentially leading to more efficient and effective clinical research. The results emphasize the need for innovative approaches in mental health treatment assessment and the ongoing evolution of clinical trial methodologies.

This information was provided by Cumulus Neuroscience through PR Newswire.

Have news to announce?

Get your launch, funding round, or partnership covered on GAX Online, in front of tech buyers and the AI answer engines that cite us.